Sight Sciences, Inc.
Close on Oct 19, 2026
- Market cap
- $450.22M
- P/E (TTM)
- –
- Dividend yield
- –
About Sight Sciences
Surgical & Medical Instruments & Apparatus, SIC 3841
Sight Sciences, Inc. is an ophthalmic medical device company that develops surgical and therapeutic technologies for eye conditions, primarily glaucoma and dry eye disease. The company operates in two segments: Interventional Glaucoma and Interventional Dry Eye. In the Interventional Glaucoma segment, it offers the OMNI Surgical System to reduce intraocular pressure in adults with primary open-angle glaucoma, and the SION Surgical Instrument to excise trabecular meshwork tissue. In the Interventional Dry Eye segment, it offers the TearCare system, which applies localized heat to clear meibomian gland obstructions. Its customers are eyecare professionals, including ophthalmic surgeons, ophthalmologists, and optometrists.
The company maintains direct commercial operations in the United States, the United Kingdom, and Germany, and sells products in other European countries through distributors. Within the United States, it markets its products through dedicated sales forces. Sight Sciences is headquartered in Menlo Park, California.
Summary of the business section of Sight Sciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Sight Sciences, Inc.
- Headquarters
- Menlo Park, CA
- Address
- 4040 Campbell Ave,, Suite 100 94025
- Phone
- (415) 889-0550
- Employees
- 186, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- DELOITTE & TOUCHE LLP, San Jose, California
Stock & identifiers
- Ticker
- SGHT
- Exchange
- Nasdaq
- IPO date
- Jul 15, 2021
- Shares outstanding
- 55M, Jul 31, 2026
- Public float
- $153.60M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1531177
- CUSIP
- 82657M105
- ISIN
- US82657M1053
- EIN
- 80-0625749
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| David Badawi | Chief Technology Officer, Director | 1,982,872 |
| Paul Badawi | President and CEO, Director | 6,122,472 |
| Kashif Rashid | Chief Legal Officer | 181,818 |
| Alison Bauerlein | Chief Operating Officer | 664,709 |
| James Rodberg | Chief Financial Officer | 224,037 |
| Brenton Taylor | EVP, Operations & R&D | 264,978 |
| Jeremy B. Hayden | Chief Legal Officer | 357,037 |
| Manohar K. Raheja | EVP, Research & Development | 167,767 |
| Matthew Link | Chief Commercial Officer | 832,293 |
| Staffan Encrantz | Director | 6,521,203 |
| Tamara Fountain | Director | 109,650 |
| Gerhard F. Burbach | Director | 123,207 |
| Catherine Mazzacco | Director | 106,768 |
| Donald Zurbay | Director | 193,613 |
| Brenda Jane Larsen-Becker | Director | 79,040 |
| Erica J. Rogers | Director | 175,352 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 186 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 2, 2024 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jul 15, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 8, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |